Noven Pharmaceuticals Inc. Completes Acquisition of Daytrana(R) Methylphenidate Transdermal System (CII) from Shire plc

MIAMI--(BUSINESS WIRE)--Noven Pharmaceuticals, Inc. today announced that it has completed the acquisition of global rights to Daytrana® (methylphenidate transdermal system) from affiliates of Shire plc (“Shire”).